[Rich66]

I guess I don't understand why Academic oncs don't get the same payback from chemos that community oncs do.
I can definitely understand involvement in a trial might influence patient management. If there is a kickback for enrollment, that doesn't seem good. Likewise, if there is incentive to select patients who are perceived to be more likely to do well/produce positive results, similarly questionable.

I don't doubt that cellular assays could test for any myriad of agents, it's just that when I contact them, endocrine testing seems very limited..I'm only aware of occassional Tamoxifen testing. I haven't encountered Faslodex, Femara, Arimidex or Aromasin as options.